第83届中国国际医药原料药/中间体/包装/设备交易会

第二十三届中国国际医药(工业)展览会暨技术交流会

开幕还剩:

距离

版权所有 © 国药励展展览有限责任公司   京ICP备06050757号                                                                                                         网站建设:中企动力 北京 Tel:13011010502

市场合作:张馨心 010-84556542     

网站合作:朱溢文 010-84556607    

会议合作:王   源 010-84556792   

NHI合作:殷   婷 010-84556505    

International Sales and marketing:Evan Wang 010-84556692

手机官网

微信公众号

                     首页                     展位预定                     观众注册                     会议论坛                     现场活动                     下载中心

新闻中心

印度制药企业欲通过产业链一体化,寻找中印合作最大公约数 APIC

来源:
国药励展
2019/08/23 14:33
【摘要】:
AccordingtoareportfromtheIndianMedicalEconomicsNews,DilipSurana,generalmanagerofMicrolabs,aleadingexport-orientedpharmaceuticalcompanyinIndia,pointedthattheIndianpharmaceuticalindustrynowhasanexcessiv

According to a report from the Indian Medical Economics News, Dilip Surana, general manager of Microlabs, a leading export-oriented pharmaceutical company in India, pointed that the Indian pharmaceutical industry now has an excessive dependence on Chinese APIs.

来自《印度医药经济信息》的报道称,印度主要出口型制药公司麦克罗( Micro labs)总经理迪利普·苏拉纳( Dilip Surana)在接受媒体采访时指出,印度制药业对中国的原料药依然有巨大的依赖。

Dilip Surana said: " Since last year (2018), due to the increased supervision of China's environmental protection, the prices of some APIs and intermediates have skyrocketed, followed by frequent supply shortages. It has made huge influence in the market, not only in China but also in India. How to avoid the dilemma of the soaring price of APIs? Many Indian pharmaceutical companies, including Micro labs, have begun to find solutions.”

 

Dilip Surana表示:“自2018年以来,受中国环保治理监管力度加大影响,部分原料药、中间体价格暴涨,随之而来的是供应短缺频繁的困扰。这些变化不仅对中国制药产业影响巨大,并且对印度的制药业也有强烈的冲击。包括Mco在内的众多印度制药企业已着手策划应对战略。“

Picture from in-Pharma Technologist

 

Indian pharmaceutical companies seek the "largest common denominator" of china-India cooperation

 

With further segmentation in the world pharmaceutical industry, the strategy to collect both upstream and downstream industry chain of pharmaceutical companies is valuable, but the cost is often too large to take with. The future approach is to establish a mutually beneficial and strategic cooperation supply chain with varied stakeholders.

随着世界制药工业分工愈来愈细,医药企业上下游产业链通吃策略虽然很有价值,但付出的成本往往也很大,前瞻的做法是与利益相关者建立互利共赢的战略合作供应链关系。

China and India, as the two largest producers and exporters of APIs in the world, have leading technologies and products respectively.

 

For example, China has strong market competitiveness in bulk fermentation, raw materials and chemical intermediates, while India has a comparative advantage in the production of high-efficiency chemical raw materials for some European and American generic drugs. It is vital for both parties to maintain a rational competitive relationship.
中国和印度作为全球两个最大的原料药生产和出口国,在各自优势资源领域均有领先的技术和产品。例如中国在大宗发酵类原料药和化学中间体的市场竞争力较强,而印度在一些欧美特色仿制药所需高效化学原料药的生产方面具有比较优势,双方保持理性的竞合关系至关重要。

Picture from: Business Line

Driven by the strict national regulatory policies such as quality, environmental protection and safety, the industrial transformation and upgrading in China's API market has accelerated, and the company in market has improved its product quality and efficiency. As a result, the industry's competitive strength has rapidly increased.

中国原料药市场在质量、环保、安全等国家监管政策趋严强化的推动下,产业转型升级加快,企业提质增效增速,行业竞争实力增强。

 

At the same time, as an industry with an outward-looking competitive advantage, the internationalization strategy of APIs should be more stable in the future. Specifically, while abandoning the phenomenon of irregular competition in excessively low-priced exports, India and must adhere to the principle of mutual benefit for trading, focus on the fairness of transactions, follow the competition rules of complementary advantages to ensure market health.

与此同时,作为具有外向型竞争优势的产业,原料药国际化经营策略也宜更加稳健。具体来说就是,在摈弃过度压价出口的不规范竞争现象的同时,要坚持诚信互利的贸易原则,关注交易公平性;遵循优势互补的竞争规律,保证市场健康性。

Picture from: Pharma IQ

It is imperative to strengthen international cooperation in the production of APIs, especially to find the largest common denominator in the cooperation of APIs in China and India, and to maximize the mutual promotion. This requires serving customers with a more rational attitude, developing a community to sharing market interests, and promoting sustainable cooperation upstream and downstream

加强原料药产能国际合作已经势在必行,特别是寻找中印两国原料药市场合作的最大公约数,对于实现互促作用最大化举足轻重。这需要服务客户更加理性,发展市场利益共同体,推进可持续合作

The 83rd API China

As the leading exhibition in Chinese pharmaceutical industry, API China converges all related parties in China for policy & regulation interpretation, prictical experience education, product showing and market information press release. During more than 40 years' development, now it also bocomes a celebration for both Chinese pharamceutical enterprises and international ones. With its great influence in the industry, API China has been recognized as the one platform for supplier sourcing and information exchanging.

 

API China作为中国制药行业的风向标,是中国制药行业各方汇聚一堂,研习最新政策法规,分享国内外企业成功经验,学习中国制药行业最新产品动态,并了解中国制药市场行业信息的极佳平台。经过41年的不断发展,API China现已成为国内外制药行业在中国不可错过的盛会。凭借其出色的行业服务水平与信息交换能力,API China成为了制药企业在中国寻源并展开商务合作的圣地。尤其是在亚洲,更吸引了众多来自印度、韩国、日本、东南亚的制药企业前来参观。